NasdaqGS:WGSHealthcare
GeneDx Holdings (WGS) Launches NPC Testing Program Following Collaboration as Valuation Stays In Focus
GeneDx Holdings (WGS) just announced a collaboration with Beren Therapeutics to launch the NPC GenomeComplete Sponsored Testing Program, offering no cost genome sequencing for pediatric patients at risk of Niemann Pick Disease Type C.
The collaboration headlines arrive after a sharp rebound in GeneDx Holdings' share price, with a 1-day share price return of 5.25% and a 90-day share price return of 48.09%. This comes even though the year-to-date share price return has fallen 32.17% and the...